SCHEMBL25819397

SCHEMBL25819397

Cc1ccc([C@@H]2CCON2C)s1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.33
POLB P06746 1/20 0.33
MAPK1 P28482 1/20 0.33
CHRM2 P08172 1/20 0.33
CHRM4 P08173 1/20 0.33
CHRM5 P08912 1/20 0.33
CHRM1 P11229 1/20 0.33
CHRM3 P20309 1/20 0.33
KDM4E B2RXH2 3/20 0.32
ALDH1A1 P00352 3/20 0.32
MEN1 O00255 2/20 0.32
MAPT P10636 2/20 0.32
THRB P10828 2/20 0.32
KMT2A Q03164 2/20 0.32
HPGD P15428 2/20 0.32
HSD17B10 Q99714 2/20 0.32
RAB9A P51151 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16661514 0.69
SCHEMBL25297193 0.69 SLC6A9 (0.34) POLBALDH1A1KMT2ARAB9ANPC1
SCHEMBL24164181 0.67 CHRM2 (0.38) SLC6A2SLC6A4SLC6A3SMN1; SMN2POLB
SCHEMBL16548495 0.66 ALDH1A1 (0.37) SLC6A2SLC6A4SLC6A3SMN1; SMN2POLB
SCHEMBL8127649 0.65 HPGD (0.42) SLC6A2SLC6A4SLC6A3SMN1; SMN2POLB
SCHEMBL15448627 0.63 NPC1 (0.49) SLC6A2SLC6A4SLC6A3SMN1; SMN2POLB
SCHEMBL23879771 0.63 SLC6A2 (0.47) SLC6A2SLC6A4SLC6A3SMN1; SMN2POLB
SCHEMBL10000241 0.63 NPC1 (0.49) SLC6A2SLC6A4SLC6A3SMN1; SMN2POLB
SCHEMBL12319410 0.62 CHRM2 (0.37) SLC6A2SLC6A4SLC6A3SMN1; SMN2CHRM2
SCHEMBL15274531 0.61 RAB9A (0.35) SLC6A2SLC6A4SLC6A3SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF SANOFI (FR) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF RIPK1, RIPK4, RIPK2 SLC6A2 4846/4885SLC6A4 4772/4885SLC6A3 4830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.